NCCN VERSION 2 2015

170 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-95
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
384. Garber K. Tamoxifen pharmacogenetics moves closer to reality. J
Natl Cancer Inst 2005;97:412-413. Available at:
.
385. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant
use, and tamoxifen metabolism during adjuvant breast cancer
treatment. J Natl Cancer Inst 2005;97:30-39. Available at:
.
386. Henry NL, Stearns V, Flockhart DA, et al. Drug interactions and
pharmacogenomics in the treatment of breast cancer and depression.
Am J Psychiatry 2008;165:1251-1255. Available at:
.
387. Ahern TP, Pedersen L, Cronin-Fenton DP, et al. No increase in
breast cancer recurrence with concurrent use of tamoxifen and some
CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev
2009;18:2562-2564. Available at:
.
388. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med
2005;353:487-497. Available at:
.
389. Li CI, Daling JR, Porter PL, et al. Relationship between potentially
modifiable lifestyle factors and risk of second primary contralateral
breast cancer among women diagnosed with estrogen receptor-positive
invasive breast cancer. J Clin Oncol 2009;27:5312-5318. Available at:
.
390. Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after
breast cancer in physically active women with high vegetable-fruit intake
regardless of obesity. J Clin Oncol 2007;25:2345-2351. Available at:
.
391. Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in
young women and its impact on reproductive function. Human
Reproduction Update 2009;15:323-339. Available at:
.
392. Moran MS, Colasanto JM, Haffty BG, et al. Effects of breast-
conserving therapy on lactation after pregnancy. Cancer J 2005;11:399-
403. Available at:
393. Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDG PET
on defining the extent of disease and on the treatment of patients with
recurrent or metastatic breast cancer. AJR Am J Roentgenol
2004;183:479-486. Available at:
.
394. Moon DH, Maddahi J, Silverman DH, et al. Accuracy of whole-
body fluorine-18-FDG PET for the detection of recurrent or metastatic
breast carcinoma. J Nucl Med 1998;39:431-435. Available at:
395. Arslan C, Sari E, Aksoy S, Altundag K. Variation in hormone
receptor and HER-2 status between primary and metastatic breast
cancer: review of the literature. Expert Opin Ther Targets 2011;15:21-
30. Available at:
396. Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2
receptor discordance between primary breast cancer and metastasis.
Oncologist 2010;15:1164-1168. Available at:
.
397. Bogina G, Bortesi L, Marconi M, et al. Comparison of hormonal
receptor and HER-2 status between breast primary tumours and
relapsing tumours: clinical implications of progesterone receptor loss.
Virchows Arch 2011;459:1-10. Available at:
.
398. Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene
variation between primary and metastatic breast cancer: significance
and impact on patient care. Clin Cancer Res 2011;17:2055-2064.
Available at: .